Stock LYRA LYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.328 USD -1.09% Intraday chart for Lyra Therapeutics, Inc. +0.77% -93.74%
May. 21 Lyra Therapeutics Reduces Workforce to Extend Cash Runway MT
May. 21 Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lyra Therapeutics Reduces Workforce to Extend Cash Runway
Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital
Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell
Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics, Inc. Announces Board Changes
Lyra Therapeutics Files $300 Million Mixed Shelf Offering
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYRA Stock
  4. News Lyra Therapeutics, Inc.
  5. Other languages